Trevi Therapeutics' Sample Size Re-estimation for Chronic Cough Trial Likely Positive, Oppenheimer Says

MT Newswires Live09-26 01:51

Trevi Therapeutics' (TRVI) upcoming sample size re-estimation for its phase 2b trial of Haduvio in refractory chronic cough is expected to yield positive results, Oppenheimer said in a note Friday.

The brokerage said it would consider a recommendation to continue the trial without any changes or increase enrollment as positive, with the upsizing scenario simply serving to increase the chance of showing statistical significance.

RBC said it would be surprised if the check results in futility, given Haduvio's clinical record across chronic cough settings. In case this happens, data from idiopathic pulmonary fibrosis-related cough studies would offer downside protection, the brokerage said.

The sample size re-estimation analysis is anticipated in Q4, with management expected to provide definitive guidance with its Q3 financial results, according to the note.

Oppenheimer has an outperform rating on the stock, with a price target of $25.

Price: 14.40, Change: -0.28, Percent Change: -1.87

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2670429188?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-26 01:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2670429188","market":"us","top_or_hot":-1,"title":"Trevi Therapeutics' Sample Size Re-estimation for Chronic Cough Trial Likely Positive, Oppenheimer Says","media":"MT Newswires Live","content":"<html><body><p> Trevi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (TRVI) upcoming sample size re-estimation for its phase 2b trial of Haduvio in refractory chronic cough is expected to yield positive results, Oppenheimer said in a note Friday.</p><p>The brokerage said it would consider a recommendation to continue the trial without any changes or increase enrollment as positive, with the upsizing scenario simply serving to increase the chance of showing statistical significance.</p><p>RBC said it would be surprised if the check results in futility, given Haduvio's clinical record across chronic cough settings. In case this happens, data from idiopathic pulmonary fibrosis-related cough studies would offer downside protection, the brokerage said.</p><p>The sample size re-estimation analysis is anticipated in Q4, with management expected to provide definitive guidance with its Q3 financial results, according to the note.</p><p>Oppenheimer has an outperform rating on the stock, with a price target of $25.</p><p>Price: 14.40, Change: -0.28, Percent Change: -1.87</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trevi Therapeutics' Sample Size Re-estimation for Chronic Cough Trial Likely Positive, Oppenheimer Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrevi Therapeutics' Sample Size Re-estimation for Chronic Cough Trial Likely Positive, Oppenheimer Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-26 01:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Trevi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (TRVI) upcoming sample size re-estimation for its phase 2b trial of Haduvio in refractory chronic cough is expected to yield positive results, Oppenheimer said in a note Friday.</p><p>The brokerage said it would consider a recommendation to continue the trial without any changes or increase enrollment as positive, with the upsizing scenario simply serving to increase the chance of showing statistical significance.</p><p>RBC said it would be surprised if the check results in futility, given Haduvio's clinical record across chronic cough settings. In case this happens, data from idiopathic pulmonary fibrosis-related cough studies would offer downside protection, the brokerage said.</p><p>The sample size re-estimation analysis is anticipated in Q4, with management expected to provide definitive guidance with its Q3 financial results, according to the note.</p><p>Oppenheimer has an outperform rating on the stock, with a price target of $25.</p><p>Price: 14.40, Change: -0.28, Percent Change: -1.87</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2670429188","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2670429188","pubTimestamp":1790358664,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Trevi Therapeutics'  upcoming sample size re-estimation for its phase 2b trial of Haduvio in refractory chronic cough is expected to yield positive results, Oppenheimer said in a note Friday.The brokerage said it would consider a recommendation to continue the trial without any changes or increase enrollment as positive, with the upsizing scenario simply serving to increase the chance of showing statistical significance.RBC said it would be surprised if the check results in futility, given Haduvio's clinical record across chronic cough settings. In case this happens, data from idiopathic pulmonary fibrosis-related cough studies would offer downside protection, the brokerage said.The sample size re-estimation analysis is anticipated in Q4, with management expected to provide definitive guidance with its Q3 financial results, according to the note.Oppenheimer has an outperform rating on the stock, with a price target of $25.Price: 14.40, Change: -0.28, Percent Change: -1.87","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4139":"生物科技","BK4007":"制药","TRVI":"Trevi Therapeutics Inc.","BK4539":"次新股"},"translate_title":"奥本海默表示，Trevi Therapeutics 对慢性咳嗽试验的样本量重新估计可能呈阳性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRVI":1,"LENZ":1.5},"content_text":"Trevi Therapeutics' (TRVI) upcoming sample size re-estimation for its phase 2b trial of Haduvio in refractory chronic cough is expected to yield positive results, Oppenheimer said in a note Friday.The brokerage said it would consider a recommendation to continue the trial without any changes or increase enrollment as positive, with the upsizing scenario simply serving to increase the chance of showing statistical significance.RBC said it would be surprised if the check results in futility, given Haduvio's clinical record across chronic cough settings. In case this happens, data from idiopathic pulmonary fibrosis-related cough studies would offer downside protection, the brokerage said.The sample size re-estimation analysis is anticipated in Q4, with management expected to provide definitive guidance with its Q3 financial results, according to the note.Oppenheimer has an outperform rating on the stock, with a price target of $25.Price: 14.40, Change: -0.28, Percent Change: -1.87","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2670429188","isCrawlerRequest":true}